Dextrose and Electrolyte No 48 and Insulin degludec and liraglutide
Determining the interaction of Dextrose and Electrolyte No 48 and Insulin degludec and liraglutide and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using liraglutide together with insulin degludec can increase the risk of hypoglycemia, or low blood sugar. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Let your doctor know if you experience hypoglycemia during treatment. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration of a glucagon-like peptide-1 (GLP-1) receptor agonist with insulin may potentiate the risk of hypoglycemia. GLP-1 receptor agonists lower blood glucose by stimulating insulin secretion and lowering glucagon secretion.
MANAGEMENT: When a GLP-1 receptor agonist is used as add-on therapy to basal insulin, a lower dosage of insulin may be required. Blood glucose should be monitored closely, and patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery. Concurrent use of GLP-1 receptor agonists with prandial insulin has not been studied and is generally not recommended.
- "Product Information. Ozempic (1 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Adlyxin (lixisenatide)." sanofi-aventis, Bridgewater, NJ.
- "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company, Indianapolis, IN.
- "Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Tanzeum (albiglutide)." GlaxoSmithKline, Research Triangle Park, NC.
- "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc, San Diego, CA.
Generic Name: lvp solution with potassium
Brand name:
Synonyms: n.a.
Generic Name: insulin degludec / liraglutide
Brand name: Xultophy
Synonyms: Insulin Degludec and Liraglutide
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dextrose and Electrolyte No 48-Insulin degludec and liraglutide Subcutaneous
- Dextrose and Electrolyte No 48-Insulin degludec Subcutaneous
- Dextrose and Electrolyte No 48-Insulin detemir
- Dextrose and Electrolyte No 48-Insulin Detemir (Cartridges and Prefilled Syringes)
- Dextrose and Electrolyte No 48-Insulin Detemir (Vials)
- Dextrose and Electrolyte No 48-Insulin detemir Subcutaneous
- Insulin degludec and liraglutide-Dextrose Chewable Tablets
- Insulin degludec and liraglutide-Dextrose Electrolyte No. 75
- Insulin degludec and liraglutide-Dextrose Gel and Liquid
- Insulin degludec and liraglutide-Dextrose Injection
- Insulin degludec and liraglutide-Dextrose Injection 10%
- Insulin degludec and liraglutide-Dextrose Injection 70%